Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- DIAGNOSIS NEWS IN BRIEF
February 12, 2001
- Aiming to Rank 20th within This Year: Mr Payne of Pharmacia
February 12, 2001
- Takeda to Carry Out Reform with Global Standard: President Takeda
February 5, 2001
- 50% of Outpatients Should Pay Fixed Rate Copayment Overall: HIB
February 5, 2001
- WORLD NEWS IN BRIEF
February 5, 2001
- Korosho Holds 1st Explanatory Meeting for Prefectural Governmental Officials -2-
February 5, 2001
- JPA Holds National Convention to Prevent Dispensing Errors
February 5, 2001
- DIAGNOSTIC NEWS IN BRIEF
February 5, 2001
- BUSINESS NEWS IN BRIEF
February 5, 2001
- Cost Curtailment Policy Should Now Target Hospitalization: JHEF Seminar
February 5, 2001
- Takara Obtains Marketing Rights for Analysis Services from GeneFormatics
February 5, 2001
- ON THE MOVE
February 5, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 5, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
February 5, 2001
- Kirin Obtains Rights to Cerus's Allogeneic Cellular Immune Therapy Technology
February 5, 2001
- NHI Prices of 12 New Ingredients Including Tamiflu, Relenza Approved
February 5, 2001
- Kissei, Teikoku Hormone to Codevelop Threatened Premature Delivery Treatment
February 5, 2001
- Peak Sales of 5 New Drugs Expected to Exceed \10 Bil.: Chuikyo
February 5, 2001
- Proposed Human Genome Research GL Explained by Kyoto Univ. Professor
February 5, 2001
- Chuikyo Members Point Out Problems with NHI Price Setting Rules
February 5, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…